Fermenta Biotech Ltd
Incorporated in 1951, Fermenta Biotech
Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
- Market Cap ₹ 539 Cr.
- Current Price ₹ 183
- High / Low ₹ 214 / 132
- Stock P/E 59.4
- Book Value ₹ 105
- Dividend Yield 0.68 %
- ROCE 3.81 %
- ROE 0.65 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 176 days to 129 days
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 7.78% over last 3 years.
- Dividend payout has been low at 6.51% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
18 | 18 | 15 | 14 | 6 | 6 | 13 | 403 | 299 | 371 | 387 | 328 | 318 | |
7 | 9 | 11 | 11 | 12 | 14 | 22 | 255 | 229 | 276 | 310 | 288 | 265 | |
Operating Profit | 11 | 9 | 4 | 3 | -6 | -8 | -9 | 148 | 70 | 95 | 77 | 40 | 53 |
OPM % | 60% | 50% | 28% | 21% | -99% | -154% | -75% | 37% | 24% | 26% | 20% | 12% | 17% |
9 | 0 | 0 | 0 | 1 | 0 | 0 | 6 | 12 | 6 | 8 | -52 | -16 | |
Interest | 0 | 0 | 0 | 0 | 2 | 6 | 11 | 21 | 20 | 19 | 18 | 21 | 20 |
Depreciation | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 12 | 15 | 19 | 24 | 25 | 23 |
Profit before tax | 18 | 7 | 2 | 1 | -9 | -18 | -23 | 121 | 48 | 63 | 43 | -59 | -6 |
Tax % | 20% | 20% | 31% | 30% | 1% | -2% | -3% | 9% | -34% | 18% | 29% | 2% | |
15 | 5 | 1 | 1 | -9 | -18 | -24 | 110 | 64 | 52 | 30 | -58 | -14 | |
EPS in Rs | 5.32 | 1.93 | 0.51 | 0.26 | -3.31 | -6.63 | -8.75 | 40.13 | 21.63 | 17.66 | 10.27 | -19.55 | -4.62 |
Dividend Payout % | 47% | 96% | 161% | 157% | -6% | -3% | -2% | 1% | 23% | 14% | 12% | -6% |
Compounded Sales Growth | |
---|---|
10 Years: | 34% |
5 Years: | 92% |
3 Years: | 3% |
TTM: | -2% |
Compounded Profit Growth | |
---|---|
10 Years: | -8% |
5 Years: | 16% |
3 Years: | -66% |
TTM: | 837% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | -5% |
3 Years: | -19% |
1 Year: | 28% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 17% |
3 Years: | 8% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 |
Reserves | 93 | 92 | 91 | 90 | 80 | 87 | 62 | 245 | 298 | 356 | 382 | 320 | 295 |
6 | 1 | 25 | 35 | 52 | 44 | 143 | 209 | 226 | 234 | 241 | 221 | 172 | |
9 | 13 | 13 | 15 | 15 | 12 | 15 | 93 | 71 | 78 | 76 | 109 | 127 | |
Total Liabilities | 110 | 107 | 131 | 143 | 149 | 146 | 223 | 551 | 610 | 683 | 713 | 665 | 608 |
12 | 10 | 8 | 7 | 93 | 94 | 96 | 177 | 197 | 250 | 287 | 258 | 236 | |
CWIP | 5 | 13 | 34 | 63 | 1 | 1 | 0 | 22 | 71 | 57 | 35 | 45 | 49 |
Investments | 36 | 32 | 39 | 40 | 41 | 40 | 118 | 8 | 1 | 13 | 13 | 16 | 4 |
57 | 53 | 51 | 33 | 15 | 12 | 9 | 344 | 341 | 363 | 378 | 346 | 320 | |
Total Assets | 110 | 107 | 131 | 143 | 149 | 146 | 223 | 551 | 610 | 683 | 713 | 665 | 608 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | 11 | 2 | -0 | -5 | -9 | 1 | 91 | 30 | 63 | 50 | 124 | |
-25 | -2 | -20 | -11 | -8 | 20 | -89 | -97 | -39 | -44 | -32 | -64 | |
-7 | -8 | 21 | 9 | 14 | -13 | 88 | 12 | -48 | -1 | -22 | -41 | |
Net Cash Flow | -0 | 1 | 2 | -2 | 1 | -2 | 1 | 6 | -57 | 18 | -4 | 19 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 5 | 12 | 9 | 5 | 2 | 26 | 8 | 59 | 94 | 95 | 111 | 75 |
Inventory Days | 347 | 501 | 392 | 328 | 317 | |||||||
Days Payable | 172 | 208 | 135 | 115 | 153 | |||||||
Cash Conversion Cycle | 5 | 12 | 9 | 5 | 2 | 26 | 8 | 234 | 387 | 352 | 324 | 239 |
Working Capital Days | -29 | -14 | -212 | -923 | -2,380 | -538 | -289 | 97 | 225 | 191 | 208 | 129 |
ROCE % | 10% | 7% | 2% | 1% | -5% | -9% | -7% | 45% | 13% | 14% | 10% | 4% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13h
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 19 Apr
-
Compliance - Compliance Certificate For The Period Ended March, 2024
19 Apr - Compliance certificate for the period from April 01, 2023 to March 31, 2024.
- Compliance Certificate Under Regulation 40(9) SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 19 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
19 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants), Regulations 2018 for the quarter ended March 31, 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Sep 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jul 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Dec 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Dec 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
Business Overview:[1][2]
a) FBL is engaged in development
and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries. It is a global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
b) Company is involved in manufacturing
of APIs for muscle relaxant and anti-flatulent applications. It delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment & management.
c) Also, company has strategic investments in subsidiaries / associate companies primarily dealing in manufacturing and marketing bulk drugs and providing services of sporting and health awareness activities / education activities.
d) Company also deals in lease rental business for ITES properties developed in Than